Eleven Biotherapeutics, Inc. (NASDAQ:EBIO)’s share price shot up 7.7% during trading on Wednesday . The stock traded as high as $0.71 and last traded at $0.70. 4,455,500 shares traded hands during mid-day trading, an increase of 835% from the average session volume of 476,490 shares. The stock had previously closed at $0.65.
A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in Eleven Biotherapeutics by 17.4% in the second quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 30,600 shares during the last quarter. Spark Investment Management LLC purchased a new position in Eleven Biotherapeutics in the second quarter valued at $148,000. Virtu KCG Holdings LLC purchased a new position in Eleven Biotherapeutics in the second quarter valued at $175,000. Finally, Municipal Employees Retirement System of Michigan purchased a new position in Eleven Biotherapeutics in the third quarter valued at $382,000. 4.19% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This story was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3078311/eleven-biotherapeutics-ebio-shares-up-7-7.html.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.